Table 2.
The effect of lung transplantation on HRQL and Valued Life Activities (LT-VLA) disability as a mediator of this effect
| SF12-PCS (MCID = 5) |
SF12-MCS (MCID = 5) |
AQ20-R (MCID = 1.75) |
EQ5D (MCID = 0.06) |
EQVAS (MCID =10) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Early | Delayed | Early | Delayed | Early | Delayed | Early | Delayed | Early | Delayed | |
| Model 1 | 15.0 (13.4, 16.7) |
−0.2 (−0.4, 0.05) |
4.9 (3.5, 6.4) |
−0.4 (−0.6, −0.2) |
7.9 (7.4, 8.4) |
−0.03 (−0.10, 0.04) |
0.17 (0.14, 0.20) |
−0.004 (−0.007, −0.0003) |
30.4 (27.5, 33.3) |
−0.4 (−0.8, −0.1) |
| Model 2 | 4.9 (3.2, 6.6) |
−0.1 (−0.4, 0.05) |
−1.0 (−2.5, 0.6) |
−0.4 (−0.5, −0.2) |
5.4 (4.8, 6.0) |
−0.01 (−0.08, 0.05) |
0.007 (−0.018, 0.032) |
−0.003 (−0.006, −0.0004) |
18.3 (15.2, 21.3) |
−0.4 (−0.7, −0.1) |
Early: From before to 3 months after transplant Delayed: 3 months after transplant to censoring which is completion of 3-year follow-up, death, dropout, or the end of the study period, whichever came first. Effect estimates reflect average change in HRQL over the early or late time period.
Model 1: Adjusted for baseline age, sex, diagnosis, baseline body mass index, forced expiratory volume in 1 second, six minute walk distance, and Lung Allocation Score; Model 2: Model 1 + change in Lung Transplant Valued Life Activities (LT-VLA) disability over time. Model 2 reflects the average change in HRQL that is not accounted for by change in LT-VLA disability.
SF12-PCS = Medical Outcomes Study Short Form 12 Physical Component Summary scale ; SF12-MCS = Medical Outcomes Study Short Form 12 Mental Component Summary scale; AQ20-R = Airway Questionnaire 20 - Revised; score reversed for ease of interpretation); EQ5D = Euroqol 5D; EQVAS = Euroqol Visual Analog Scale; MCID = Minimally Clinically Important Difference